ReviewAdvances and technical standards in neurosurgery2026
Pineal Tumors and Pineal Region Tumors.
Review in Advances and technical standards in neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumors of the pineal region (PRTs) are rare and heterogeneous, accounting for less than 1% of intracranial neoplasms. They encompass pineal parenchymal tumors (PPTs), germ cell tumors (GCTs), and other histologies, such as gliomas or meningiomas. Radiotherapy remains a cornerstone of their management, with techniques and doses tailored to tumor biology and dissemination risk.
methodsThis review summarizes current principles and practices in radiotherapy for PRTs, based on tumor subtype and extent of disease.
resultsFor pineocytoma (WHO grade I), gross total resection (GTR) provides excellent outcomes, while adjuvant radiotherapy (50-54 Gy) or stereotactic radiosurgery (SRS) is reserved for subtotally resected cases. Pineal parenchymal tumors of intermediate differentiation (PPTIDs) (grades II-III) display variable aggressiveness; GTR remains the main prognostic factor, and adjuvant RT (50-54 Gy) improves overall survival, with craniospinal irradiation (CSI, 23-36 Gy + boost) indicated in disseminated disease. Pineoblastoma (PB) is an aggressive embryonal tumor requiring multimodal therapy: CSI (36 Gy + boost to 54-55.8 Gy) combined with chemotherapy yields 5-year OS rates >70% in children ≥3 years, though outcomes remain poor in younger or metastatic patients. Papillary tumor of the pineal region (PTPR) (WHO II-III) typically recurs locally despite surgery; adjuvant focal radiotherapy (≈50 Gy) is recommended. The recently described desmoplastic myxoid tumor, SMARCB1-mutant shows intermediate behavior, with limited data supporting focal RT ≥54 Gy. Among germ cell tumors, pure germinomas-highly radiosensitive-achieve >90% 5-year OS with reduced-volume RT whole-ventricular irradiation (WVI, 24 Gy + boost) has replaced historical CSI. Non-germinomatous GCTs (NGGCTs) require combined chemotherapy and RT; CSI + boost achieves 70-90% 5-year OS. Proton therapy is increasingly employed to limit long-term neurocognitive and secondary cancer risks.
conclusionsManagement of pineal region tumors relies on an integrated approach combining surgery, radiotherapy, and, when indicated, chemotherapy. Advances in conformal and particle techniques have optimized the therapeutic ratio, while molecular classification now guides risk-adapted treatment. Future studies should refine dose-volume strategies and integrate biological markers to further personalize care.
Indexed as
Identifiers
42115465What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.